FDA advisors vote 21-0, with one abstention, to authorize Novavax’s Covid-19 vaccine to be the fourth US option
A panel of FDA’s outside experts recommended 21 to 0, with one member abstaining, that the agency give emergency use authorization for Novavax’s two-dose Covid-19 vaccine for people aged 18 years and older.
The advisors’ vote of confidence was delivered days after the FDA’s scientists determined the vaccine to be effective but with the caveat of potential rare heart inflammation. Last autumn, pre-Omicron, the vaccine was found to have a 90.4% efficacy in a trial comprising 17,272 people given a vaccine and 8,385 people given a placebo.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,100+ biopharma pros reading Endpoints daily — and it's free.